Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs

Giovanni Corrao, Antonella Zambon, Silvia Faini, Vincenzo Bagnardi, Olivia Leoni, Samy Suissa

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The effect of short-acting inhaled β 2-agonists on mortality from chronic obstructive pulmonary disease (COPD) is controversial. Different observational designs were used to investigate about this topic. A population-based case-control design was performed, by linking automated health databases from the Varese Province of Italy. Deaths of COPD generated from the cohort of 135,871 patients for whom at least one prescription for drugs used to treat COPD had been dispensed between 1997 and 1999 entered into the study as cases. Up to 20 controls were randomly selected for each case from the cohort after matching on gender, age, and date of cohort entry. Risk ratios were estimated using the case-control, case-crossover, and case-time-control approaches. A total of 222 cases and 3022 controls met the inclusion criteria. Odds ratios (and corresponding 95% confidence intervals) corresponding to more than 0.5 defined-daily-doses were 2.6 (1.7, 4.0), 1.9 (1.1, 3.3), 2.1 (1.1, 4.0), and 2.3 (1.2, 4.6) by using crude and adjusted case-control, case-crossover, and case-time-control estimates, respectively. Evidence that higher doses of short-acting inhaled β 2-agonists are associated with higher mortality from COPD was consistently supplied by three observational approaches.

Original languageEnglish
Pages (from-to)92-97
Number of pages6
JournalJournal of Clinical Epidemiology
Volume58
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Chronic Obstructive Pulmonary Disease
Mortality
Odds Ratio
Prescription Drugs
Italy
Databases
Confidence Intervals
Health
Population

Keywords

  • Automated databases
  • Beta-agonists
  • Case-control
  • Case-crossover design
  • Case-time-control design
  • Chronic obstructive pulmonary disease

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. / Corrao, Giovanni; Zambon, Antonella; Faini, Silvia; Bagnardi, Vincenzo; Leoni, Olivia; Suissa, Samy.

In: Journal of Clinical Epidemiology, Vol. 58, No. 1, 01.2005, p. 92-97.

Research output: Contribution to journalArticle

Corrao, Giovanni ; Zambon, Antonella ; Faini, Silvia ; Bagnardi, Vincenzo ; Leoni, Olivia ; Suissa, Samy. / Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. In: Journal of Clinical Epidemiology. 2005 ; Vol. 58, No. 1. pp. 92-97.
@article{a3bff220f88b437bb8de8c4c3ce12cf3,
title = "Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs",
abstract = "The effect of short-acting inhaled β 2-agonists on mortality from chronic obstructive pulmonary disease (COPD) is controversial. Different observational designs were used to investigate about this topic. A population-based case-control design was performed, by linking automated health databases from the Varese Province of Italy. Deaths of COPD generated from the cohort of 135,871 patients for whom at least one prescription for drugs used to treat COPD had been dispensed between 1997 and 1999 entered into the study as cases. Up to 20 controls were randomly selected for each case from the cohort after matching on gender, age, and date of cohort entry. Risk ratios were estimated using the case-control, case-crossover, and case-time-control approaches. A total of 222 cases and 3022 controls met the inclusion criteria. Odds ratios (and corresponding 95{\%} confidence intervals) corresponding to more than 0.5 defined-daily-doses were 2.6 (1.7, 4.0), 1.9 (1.1, 3.3), 2.1 (1.1, 4.0), and 2.3 (1.2, 4.6) by using crude and adjusted case-control, case-crossover, and case-time-control estimates, respectively. Evidence that higher doses of short-acting inhaled β 2-agonists are associated with higher mortality from COPD was consistently supplied by three observational approaches.",
keywords = "Automated databases, Beta-agonists, Case-control, Case-crossover design, Case-time-control design, Chronic obstructive pulmonary disease",
author = "Giovanni Corrao and Antonella Zambon and Silvia Faini and Vincenzo Bagnardi and Olivia Leoni and Samy Suissa",
year = "2005",
month = "1",
doi = "10.1016/j.jclinepi.2004.04.013",
language = "English",
volume = "58",
pages = "92--97",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs

AU - Corrao, Giovanni

AU - Zambon, Antonella

AU - Faini, Silvia

AU - Bagnardi, Vincenzo

AU - Leoni, Olivia

AU - Suissa, Samy

PY - 2005/1

Y1 - 2005/1

N2 - The effect of short-acting inhaled β 2-agonists on mortality from chronic obstructive pulmonary disease (COPD) is controversial. Different observational designs were used to investigate about this topic. A population-based case-control design was performed, by linking automated health databases from the Varese Province of Italy. Deaths of COPD generated from the cohort of 135,871 patients for whom at least one prescription for drugs used to treat COPD had been dispensed between 1997 and 1999 entered into the study as cases. Up to 20 controls were randomly selected for each case from the cohort after matching on gender, age, and date of cohort entry. Risk ratios were estimated using the case-control, case-crossover, and case-time-control approaches. A total of 222 cases and 3022 controls met the inclusion criteria. Odds ratios (and corresponding 95% confidence intervals) corresponding to more than 0.5 defined-daily-doses were 2.6 (1.7, 4.0), 1.9 (1.1, 3.3), 2.1 (1.1, 4.0), and 2.3 (1.2, 4.6) by using crude and adjusted case-control, case-crossover, and case-time-control estimates, respectively. Evidence that higher doses of short-acting inhaled β 2-agonists are associated with higher mortality from COPD was consistently supplied by three observational approaches.

AB - The effect of short-acting inhaled β 2-agonists on mortality from chronic obstructive pulmonary disease (COPD) is controversial. Different observational designs were used to investigate about this topic. A population-based case-control design was performed, by linking automated health databases from the Varese Province of Italy. Deaths of COPD generated from the cohort of 135,871 patients for whom at least one prescription for drugs used to treat COPD had been dispensed between 1997 and 1999 entered into the study as cases. Up to 20 controls were randomly selected for each case from the cohort after matching on gender, age, and date of cohort entry. Risk ratios were estimated using the case-control, case-crossover, and case-time-control approaches. A total of 222 cases and 3022 controls met the inclusion criteria. Odds ratios (and corresponding 95% confidence intervals) corresponding to more than 0.5 defined-daily-doses were 2.6 (1.7, 4.0), 1.9 (1.1, 3.3), 2.1 (1.1, 4.0), and 2.3 (1.2, 4.6) by using crude and adjusted case-control, case-crossover, and case-time-control estimates, respectively. Evidence that higher doses of short-acting inhaled β 2-agonists are associated with higher mortality from COPD was consistently supplied by three observational approaches.

KW - Automated databases

KW - Beta-agonists

KW - Case-control

KW - Case-crossover design

KW - Case-time-control design

KW - Chronic obstructive pulmonary disease

UR - http://www.scopus.com/inward/record.url?scp=11844278489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844278489&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2004.04.013

DO - 10.1016/j.jclinepi.2004.04.013

M3 - Article

VL - 58

SP - 92

EP - 97

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 1

ER -